Validation of circulating BNP level >1000pg/ml in all-cause mortality: A retrospective study
Validation of circulating BNP level >1000pg/ml in all-cause mortality: A retrospective study
复制标题
DOI：
10.1177/0300060515583077
复制
发表时间：
2015-08-01
影响因子：
1.6
通讯作者：
Kanda, Tsugiyasu
中科院分区：
文献类型：
--
作者：
Sakamoto, Daisuke;Sakamoto, Shigeru;Kanda, Tsugiyasu
目的探讨伴有或不伴有心力衰竭的b型利钠肽（BNP; >1000pg/ml）高水平升高患者的原发疾病及预后。方法病历和超声心动图显示，BNP水平在3个预定类别(bb0 1000pg/ml、200-1000pg/ml和1000pg/ml （n=103）或200-1000pg/ml （n=100）的患者3年生存率明显低于BNP水平为1000pg/ml组的心力衰竭患者。其他原因BNP水平为bb0 1000pg/ml（39/103）的患者死亡的主要原因是社区获得性肺炎。结论BNP水平>1000pg/ml在基层医疗和医院有重要的临床意义。
AimTo determine the primary diseases and prognoses of patients with highly elevated levels of B-type natriuretic peptide (BNP; >1000pg/ml), with or without heart failure. MethodsMedical records and echocardiograms of patients with BNP levels that fell within one of three predetermined categories (>1000pg/ml, 200-1000pg/ml and 1000pg/ml (n=103) or 200-1000pg/ml (n=100) had significantly worse 3-year survival than those with BNP levels 1000pg/ml group had heart failure. The main cause of death in patients with other causes of BNP levels >1000pg/ml (39/103) was community acquired pneumonia. ConclusionA BNP level >1000pg/ml has clinical importance in primary care medicine and hospital settings.